Navigation Links
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
Date:7/25/2012

development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with U.S.-based Jennerex Biotherapeutics, Inc., to develop and market JX-594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available on the internet at www.transgene.fr

Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at '/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... leading,developer of medical simulation systems, today announced an agreement ... and related,products. , Johnson & ... and,is one of the subsidiaries of Johnson & Johnson. ... will have exclusive rights to distribute,Simbionix,s line of advanced ...
... Newly Diagnosed Patients Receive a Drug Within One Year ... from Decision ResourcesWALTHAM, Mass., April 15 /PRNewswire/ ... leading research and advisory firms focusing on pharmaceutical and ... than 30 percent of their use of emerging oral ...
Cached Medicine Technology:Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 3
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
(Date:7/9/2014)... flatulence and have a reputation for being highly toxic, but ... now being being found to offer potential health benefits in ... and dementia. A new compound (AP39), designed and made at ... therapies, by targeting delivery of very small amounts of the ... , Scientists in Exeter have already found that the compound ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... 2008 -- Women born after 1944 began drinking alcohol at ... put them at greater risk for alcoholism, according to researchers ... On average, women born before 1944 began drinking at age ... 17, and they had a 50 to 80 percent greater ...
... and ... Launch in Spanish, CHICAGO and ... in health education, and Merck & Co.,Inc., a global research-driven pharmaceutical ... multi-year relationship,to transform how healthcare professionals engage patients in learning about,diabetes ...
... June 5 Nuvelo, Inc.,(Nasdaq: NUVO ) ... the,company,s Wnt Therapeutics program showing that the R-spondin ... pathway that is critical for,cell growth and differentiation ... the activity of Wnt proteins, and,modulated the Wnt ...
... FALLS CHURCH, Va., June 5 CSC (NYSE: ... LLC (DVC), a CSC company, has been,notified by ... funding for,advanced development of plague vaccine will be ... Project Manager Chemical, Biological and,Medical Systems, Joint Vaccine ...
... of alcohol a week can trim that risk by 50%, ... who drink alcohol regularly may cut their risk of developing ... been shown to reduce the risk of cardiovascular disease, and ... risk of rheumatoid arthritis by up to 50 percent. This ...
... LEAN CUISINE(R) are Nutritious and Delicious, SOLON, Ohio, ... know they,re good for us and want to reap ... how to incorporate them into,convenient and tasty meals. A ... benefits of the Omega-3 fatty acids DHA and,EPA. These ...
Cached Medicine News:Health News:Initiating drinking at younger age heightens women's risk for alcohol dependence 2Health News:Initiating drinking at younger age heightens women's risk for alcohol dependence 3Health News:Healthy Interactions and Merck Announce Further Collaboration to Transform Diabetes Education in the U.S. 2Health News:Healthy Interactions and Merck Announce Further Collaboration to Transform Diabetes Education in the U.S. 3Health News:Healthy Interactions and Merck Announce Further Collaboration to Transform Diabetes Education in the U.S. 4Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 2Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 3Health News:CSC's DynPort Vaccine Company to Continue Plague Vaccine Development 2Health News:CSC's DynPort Vaccine Company to Continue Plague Vaccine Development 3Health News:Drinking Cuts Rheumatoid Arthritis Risk 2Health News:Drinking Cuts Rheumatoid Arthritis Risk 3Health News:Now You Can Have Your Fish and Enjoy It Too... 2Health News:Now You Can Have Your Fish and Enjoy It Too... 3
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
Medicine Products: